{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-24-000160","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.307961+00:00","generated_at":"2026-05-30T04:24:57.742009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M","bullets":["Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).","Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).","GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.","Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-24-000160","json":"https://secwatch.observer/filing/0001384101-24-000160.json","markdown":"https://secwatch.observer/filing/0001384101-24-000160.md","text":"https://secwatch.observer/filing/0001384101-24-000160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/0001384101-24-000160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000160/vcyt-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:24:57.742009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}